[["index.html", "A Minimal Book Example 1 Prerequisites", " A Minimal Book Example Yihui Xie 2020-11-20 1 Prerequisites This is a sample book written in Markdown. You can use anything that Pandocs Markdown supports, e.g., a math equation \\(a^2 + b^2 = c^2\\). The bookdown package can be installed from CRAN or Github: install.packages(&quot;bookdown&quot; &quot;clinicalfd&quot;) # or the development version # devtools::install_github(&quot;rstudio/bookdown&quot;) Remember each Rmd file contains one and only one chapter, and a chapter is defined by the first-level heading #. To compile this example to PDF, you need XeLaTeX. You are recommended to install TinyTeX (which includes XeLaTeX): https://yihui.org/tinytex/. "],["intro.html", "2 Introduction", " 2 Introduction You can label chapter and section titles using {#label} after them, e.g., we can reference Chapter 2. If you do not manually label them, there will be automatic labels anyway, e.g., Chapter 8. Figures and tables with captions will be placed in figure and table environments, respectively. What is R? * R is a free language and environment for statistical computing and graphics. You can perform a variety of tasks using R language. Some are as follows - Exploring and Manipulating Data Building and validating predictive models Applying machine learning and text mining algorithms Creating visual appealing graphs Connecting with Databases Building online dynamic reports or dashboards Send emails or push notification via R What is RStudio and its benefits over standard R? RStudio was built to make your life easy as a R programmer. It is available in open source for FREE. Unlike standard R, it supports various premium features such as intelligent code completion, syntax highlighting, structured R documentation, interactive debugging tool etc. Some Useful RStudio Shortcuts Press CTRL + Enter to submit code Press CTRL + SHIFT + C to comment/ uncomment code Press CTRL + SHIFT + N to create a new R script ###Basics of R Programming### Write your first equation in R Enter 5*3 in the RStudio code editor window and hit CTRL + ENTER in RStudio (or press F5 in standard R) # Write your first equation in R 5 * 3 ## [1] 15 The [1] tells you the resulting value is the first result The # at the beginning of a line signifies a comment Try Shift+Cntrl+c on Rstudio NOTE : ### has different meaning in R-Markdown syntax The operator &lt;- is equivalent to = sign, you can use either of the operators. NOTE: &lt;- is preferred to = in R as assignment operator setwd() function assigns a working directory setwd() is similar to Libname in SAS envirnoment getwd() function shows working directory R uses NA getwd() The table below summarizes the treatment variables and population flags that exist among different groups of analysis requirements: par(mar = c(4, 4, .1, .1)) plot(pressure, type = &#39;b&#39;, pch = 19) Figure 2.1: Here is a nice figure! Reference a figure by its code chunk label with the fig: prefix, e.g., see Figure 2.1. Similarly, you can reference tables generated from knitr::kable(), e.g., see Table 2.1. knitr::kable( head(iris, 20), caption = &#39;Here is a nice table!&#39;, booktabs = TRUE ) Table 2.1: Here is a nice table! Sepal.Length Sepal.Width Petal.Length Petal.Width Species 5.1 3.5 1.4 0.2 setosa 4.9 3.0 1.4 0.2 setosa 4.7 3.2 1.3 0.2 setosa 4.6 3.1 1.5 0.2 setosa 5.0 3.6 1.4 0.2 setosa 5.4 3.9 1.7 0.4 setosa 4.6 3.4 1.4 0.3 setosa 5.0 3.4 1.5 0.2 setosa 4.4 2.9 1.4 0.2 setosa 4.9 3.1 1.5 0.1 setosa 5.4 3.7 1.5 0.2 setosa 4.8 3.4 1.6 0.2 setosa 4.8 3.0 1.4 0.1 setosa 4.3 3.0 1.1 0.1 setosa 5.8 4.0 1.2 0.2 setosa 5.7 4.4 1.5 0.4 setosa 5.4 3.9 1.3 0.4 setosa 5.1 3.5 1.4 0.3 setosa 5.7 3.8 1.7 0.3 setosa 5.1 3.8 1.5 0.3 setosa adsl &lt;- clinicalfd::adsl head(adsl) ## studyid usubjid subjid siteid sitegr1 arm ## 1 CDISCPILOT01 01-701-1015 1015 701 701 Placebo ## 2 CDISCPILOT01 01-701-1023 1023 701 701 Placebo ## 3 CDISCPILOT01 01-701-1028 1028 701 701 Xanomeline High Dose ## 4 CDISCPILOT01 01-701-1033 1033 701 701 Xanomeline Low Dose ## 5 CDISCPILOT01 01-701-1034 1034 701 701 Xanomeline High Dose ## 6 CDISCPILOT01 01-701-1047 1047 701 701 Placebo ## trt01p trt01pn trt01a trt01an trtsdt ## 1 Placebo 0 Placebo 0 2014-01-02 ## 2 Placebo 0 Placebo 0 2012-08-05 ## 3 Xanomeline High Dose 81 Xanomeline High Dose 81 2013-07-19 ## 4 Xanomeline Low Dose 54 Xanomeline Low Dose 54 2014-03-18 ## 5 Xanomeline High Dose 81 Xanomeline High Dose 81 2014-07-01 ## 6 Placebo 0 Placebo 0 2013-02-12 ## trtedt trtdur avgdd cumdose age agegr1 agegr1n ageu race racen sex ## 1 2014-07-02 182 0.0 0 63 &lt;65 1 YEARS WHITE 1 F ## 2 2012-09-01 28 0.0 0 64 &lt;65 1 YEARS WHITE 1 M ## 3 2014-01-14 180 77.7 13986 71 65-80 2 YEARS WHITE 1 M ## 4 2014-03-31 14 54.0 756 74 65-80 2 YEARS WHITE 1 M ## 5 2014-12-30 183 76.9 14067 77 65-80 2 YEARS WHITE 1 F ## 6 2013-03-09 26 0.0 0 85 &gt;80 3 YEARS WHITE 1 F ## ethnic saffl ittfl efffl comp8fl comp16fl comp24fl disconfl ## 1 HISPANIC OR LATINO Y Y Y Y Y Y ## 2 HISPANIC OR LATINO Y Y Y N N N Y ## 3 NOT HISPANIC OR LATINO Y Y Y Y Y Y ## 4 NOT HISPANIC OR LATINO Y Y Y N N N Y ## 5 NOT HISPANIC OR LATINO Y Y Y Y Y Y ## 6 NOT HISPANIC OR LATINO Y Y Y N N N Y ## dsraefl dthfl bmibl bmiblgr1 heightbl weightbl educlvl disonsdt durdis ## 1 25.1 25-&lt;30 147.3 54.4 16 2010-04-30 43.9 ## 2 Y 30.4 &gt;=30 162.6 80.3 14 2006-03-11 76.4 ## 3 31.4 &gt;=30 177.8 99.3 16 2009-12-16 42.8 ## 4 28.8 25-&lt;30 175.3 88.5 12 2009-08-02 55.3 ## 5 26.1 25-&lt;30 154.9 62.6 9 2011-09-29 32.9 ## 6 Y 30.4 &gt;=30 148.6 67.1 8 2009-07-26 42.0 ## durdsgr1 visit1dt rfstdtc rfendtc visnumen rfendt ## 1 &gt;=12 2013-12-26 2014-01-02 2014-07-02 12 2014-07-02 ## 2 &gt;=12 2012-07-22 2012-08-05 2012-09-02 5 2012-09-02 ## 3 &gt;=12 2013-07-11 2013-07-19 2014-01-14 12 2014-01-14 ## 4 &gt;=12 2014-03-10 2014-03-18 2014-04-14 5 2014-04-14 ## 5 &gt;=12 2014-06-24 2014-07-01 2014-12-30 12 2014-12-30 ## 6 &gt;=12 2013-01-22 2013-02-12 2013-03-29 6 2013-03-29 ## dcdecod dcreascd mmsetot ## 1 COMPLETED Completed 23 ## 2 ADVERSE EVENT Adverse Event 23 ## 3 COMPLETED Completed 23 ## 4 STUDY TERMINATED BY SPONSOR Sponsor Decision 23 ## 5 COMPLETED Completed 21 ## 6 ADVERSE EVENT Adverse Event 23 "],["study-cdisc-pilot01-guide.html", "3 Study CDISC Pilot01 Guide", " 3 Study CDISC Pilot01 Guide Note on Input Data Sources The analysis files for this study were derived from the submitted SDTM files. SDTM files were prepared from CRF data according to version 3.1.2 of the SDTM IG (with amendment 1). No non-CRF or non-SDTM data were used to create the ADaM data. The datasets include only subjects who were enrolled in the study. Subjects who failed screening criteria were not included in analysis datasets. Where to Find Key Data Demographics and Populations The ADSL (Subject Level Analysis Data) dataset contains all subject-level variables for demographics, subject characteristics, and population flags. Safety Key safety data are found in the datasets ADAE (Adverse Events Analysis Data), ADLBC (Laboratory Results Chemistry Analysis Data), ADLBH (Laboratory Results Hematology Analysis Data), ADLBHY (Laboratory Results Hys Rule Analysis Data), ADVS (Vital Signs Analysis Dataset). ADTTE is specifically for safety analyses of the time to the first dermatologic AE. Dermatologic AEs are considered an adverse event of special interest. Efficacy Study CDISCPilot01 has two primary endpoints, the Alzheimers Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Week 24 and the Video-referenced Clinicians Interview-based Impression of Change (CIBIC+) at Week 24. All ADAS-Cog data, including the first primary endpoint, can be found in the dataset ADQSADAS. All CIBIC+ data, including the second primary endpoint, can be found in the dataset ADQSCIBC. Mean Revised Neuropsychiatric Inventory (NPI-X) data are considered secondary. These data can be found in the dataset ADQSNPIX. Protocol Deviations Protocol deviations were not reported in the source database and have not been incorporated into the SDTM data. As a result, such data do not exist among the analysis data. Core Variables The following core variables were merged from ADSL into all analysis datasets: STUDYID, SITEID, USUBJID, TRTSDT, TRTEDT, AGE, AGEGR1, AGEGR1N, SEX, RACE, and RACEN. The table below summarizes the treatment variables and population flags that exist among different groups of analysis requirements: Dataset(s) Treatment Variables Population Flags ADSL TRT01P, TRT01PN, TRT01A,TRT01AN SAFFL, DSRAEFL,ITTFL, EFFFL,COMP24FL ADAE TRTA, TRTAN SAFFL ADLBH,ADLBC, ADLBHY TRTP, TRTPN, TRTA,TRTAN SAFFL,COMP24FL,DSRAEFL ADVS TRTP, TRTPN, TRTA,TRTAN SAFFL ADTTE TRTP, TRTA, TRTAN SAFFL ADQSADAS, ADQSNPIX, ADQSCIBC TRTP, TRTPN ITTFL, EFFFL,COMP24FL Treatment variable values are based on the numeric dose level (i.e., 0, 54, 81) to avoid the need for a separate variable that contains the treatment dose. "],["overview-of-analysis-datasets.html", "4 Overview of Analysis Datasets 4.1 ADAE  Adverse Events Analysis Data 4.2 ADLBHY  Laboratory Results Hys Rule Analysis Data 4.3 ADQSADAS  ADAS-COG Data 4.4 ADQSCIBC  CIBC Data 4.5 ADQSNPIX  NPI-X Item Analysis Data", " 4 Overview of Analysis Datasets Overview of Analysis Datasets Important information regarding specific analysis data sets can be found below. For full details of all analysis data sets, including key analysis results 4.1 ADAE  Adverse Events Analysis Data ADAE contains one record per reported event per subject. Subjects who did not report any Adverse Events are not represented in this dataset. The data reference for ADAE is the SDTM AE (Adverse Events) domain and there is a 1-1 correspondence between records in the source and this analysis dataset. These records can be linked uniquely by STUDYID, USUBJID, and AESEQ. As with the SDTM AE data set, all MedDRA code variables (i.e. those variables that end in CD) have missing values and dummy terms have been applied to the MedDRA High Level Term (HLT) and High Level Group Term (HLGT). This is due to the proprietary nature of the MedDRA dictionary and the fact that the data with this project will be made available to the public. In a standard submission, these codes and terms should be non-missing and properly populated. Events of particular interest (dermatologic) are captured in the customized query variable (CQ01NAM) in this dataset.Since ADAE is a source for ADTTE, the first chronological occurrence based on the start dates (and sequence numbers) of the treatment emergent dermatological events are flagged (AOCC01FL) to facilitate traceability between these two analysis datasets. ADAE also contains additional Occurrence Flags to facilitate traceability, reviewability, and easy of reporting between the analysis dataset and the unique counts in the summary tables. For treatment emergent adverse events refer to define.xml documentation for the following variables: AOCCFL, AOCCSFL, and AOCCPFL for summarization at the subject,System Organ Class, and Preferred Term levels, respectively. Similarly, refer to the define.xml documentation for AOCC02FL, AOCC03FL, and AOCC04FL for summarization of serious adverse events at the subject, System Organ Class, and Preferred Term levels. The three deaths reported during the conduct of this study are captured in the Results in Death Flag (AESDTH=Y) and Outcome of Adverse Event (AEOUT=FATAL). The Start Date of the Adverse Event in ADAE is imputed to the first of the month if the day is missing. The Study Day of Event Start (ASTDY) and the Treatment Emergent Analysis Flag (TRTEMFL) are derived based on this imputation and may differ from their corresponding SDTM AE/SUPPAE variables Study Day of Start of Adverse Event (AESTDY) and Treatment Emergent Flag (AETRTEM). ADLBC&amp;BH  Laboratory Results Chemistry/Hematology Analysis Data** ADLBC and ADLBH contain one record per lab analysis parameter, per time point, per subject.** ADLBC contains lab chemistry parameters and ADLBH contains hematology parameters and these data are derived from the SDTM LB (Laboratory Tests) domain. Two sets of lab parameters exist in ADLBC/ADLBH. One set contains the standardized lab value from the LB domain and the second set contains change from previous visit relative to normal range values. In some of the summaries the derived end-of-treatment visit (AVISITN=99) is also presented. 4.2 ADLBHY  Laboratory Results Hys Rule Analysis Data ADLBHY contains one record per lab test code per sample, per subject for the Hys Law based analysis parameters. ADLBHY is derived from the ADLBC (Laboratory Results Chemistry Analysis Data) analysis dataset. It contains derived parameters based on Hys law. 4.3 ADQSADAS  ADAS-COG Data ADQSADAS contains analysis data from the ADAS-Cog questionnaire, one of the primary efficacy endpoints. It contains one record per subject per parameter (ADAS-Cog questionnaire item) per VISIT. Visits are placed into analysis visits (represented by AVISIT and AVISITN) based on the date of the visit and the visit windows. If multiple visits fall into the same visit window, then the one closest to the target date is chosen for analysis. Records where ANL01FL=Y are the ones that were used for analysis. The last observation carried forward (LOCF) algorithm only considered records used for analysis as candidates to carry forward. Records where DTYPE=LOCF signify those where AVAL was imputed using the LOCF algorithm. Source data can be traced back to the SDTM.QS domain using USUBJID and QSSEQ.Details on how to derive the primary efficacy result based on ADAS-Cog data can be found in the analysis results metadata in the define.xml. 4.4 ADQSCIBC  CIBC Data ADQSCIBC contains analysis data from the from CIBIC+ questionnaire, one of the primary efficacy endpoints. It contains one record per subject per VISIT. Note that for all records, PARAM=CIBIC Score. Visits are placed into analysis visits (represented by AVISIT and AVISITN) based on the date of the visit and the visit windows. If multiple visits fall into the same visit window, then the one closest to the target date is chosen for analysis. Records where ANL01FL=Y are the ones that were used for analysis. The last observation carried forward (LOCF) algorithm only considered records used for analysis as candidates to carry forward. Records where DTYPE=LOCF signify those where AVAL was imputed using the LOCF algorithm. Source data can be traced back to the SDTM.QS domain using USUBJID and QSSEQ. Details on how to derive the primary efficacy result based on CIBIC+ data can be found in the analysis results metadata in the define.xml. 4.5 ADQSNPIX  NPI-X Item Analysis Data ADQSNPIX contains one record per subject per parameter (NPI-X questionnaire item, total score, and mean total score from Week 4 through Week 24) per analysis visit (AVISIT). The analysis visits (represented by AVISIT and AVISITN) are derived from days between assessment date and randomization date and based on the visit windows that were specified in the statistical analysis plan (SAP). If multiple assessments fall into the same visit window, then the one closest to the target day is chosen for analysis. Records where analysis flag (ANL01FL) = Y are the ones that were used for analysis. The last observation carried forward (LOCF) algorithm was not used for these data. Source data can be traced back to the SDTM.QS domain using USUBJID and QSSEQ. All the NPI-X parameters, except for the mean total score from Week 4 through Week 24 (NPTOTMN), are from SDTM.QS domain. The value of parameter, NPTOTMN, contains the mean total score for each patient who had any assessments from Week 4 through Week 24. The baseline value of the parameter, NPTOTMN, is the same as the baseline value of total score. The baseline value is a covariate in the analysis of covariance (ANCOVA) model. "],["adam-datasets-for-study-cdisc-pilot-01.html", "5 ADaM Datasets for Study CDISC PILOT 01", " 5 ADaM Datasets for Study CDISC PILOT 01 Adam Datasets List Dataset Description Class Structure Keys Location ADSL Subject-Level Analysis ADSL one record per subject USUBJID adsl.xpt ADAE Adverse Events Analysis Dataset ADAE one record per subject per adverse event USUBJID, AETERM, ASTDT, AESEQ adae.xpt ADLBC Analysis Dataset Lab Blood Chemistry BDS one record per subject per parameter per analysis visit USUBJID, PARAMCD, AVISIT, LBSEQ adlbc.xpt ADLBH Analysis Dataset Lab Hematology BDS one record per subject per parameter per analysis visit USUBJID, PARAMCD, AVISIT, LBSEQ adlbh.xpt ADLBHY Analysis Dataset Lab Hys Law BDS one record per subject per parameter per analysis visit USUBJID, PARAMCD, AVISIT, LBSEQ adlbhy.xpt ADQSADAS ADAS-Cog Analysis BDS one record per subject per parameter per analysis visit per analysis date USUBJID, PARAMCD, AVISIT, ADT adqsadas.xpt ADQSCIBC CIBIC+ Analysis BDS one record per subject per parameter per analysis visit per analysis date USUBJID, PARAMCD, AVISIT, ADT adqscibc.xpt ADQSNPIX NPI-X Item Analysis Data BDS one record per subject per parameter per analysis visit per analysis date USUBJID, PARAMCD, AVISIT, ADT adqsnpix.xpt ADTTE AE Time To 1st Derm. Event Analysis BDS one record per subject per parameter USUBJID, PARAMCD adtte.xpt ADVS Vital Signs Analysis Dataset BDS one record per subject per parameter per analysis visit per analysis timepoint USUBJID, PARAMCD, AVISIT, ATPT advs.xpt "],["subject-level-analysis-adsl.html", "6 Subject-Level Analysis (ADSL)", " 6 Subject-Level Analysis (ADSL) NOTE: Derived = 1 is direct copy from SDTM.DM or Other SDTM dataset , while Derived = 2 needs further imputation. Variable Label Type Code List / Controlled Terms Derived Source/Derivation/Comments STUDYID Study Identifier text 1 DM.STUDYID USUBJID Unique Subject Identifier text 1 DM.USUBJID SUBJID Subject Identifier for the Study text 1 DM.SUBJID SITEID Study Site Identifier text 1 DM.SITEID ARM Description of Planned Arm text ARM 1 DM.ARM TRT01P Planned Treatment for Period 01 text ARM 1 DM.ARM TRT01PN Planned Treatment for Period 01 (N) integer ARMN 1 Numeric code for TRT01P which corresponds to the randomized dose TRT01A Actual Treatment for Period 01 text ARM 1 TRT01A=TRT01P, i.e., no difference between actual and randomized treatment in this study. TRT01AN Actual Treatment for Period 01 (N) integer ARMN 1 Numeric code for TRT01A which corresponds to the randomized dose AGE Age integer 1 DM.AGE AGEU Age Units text AGEU 1 DM.AGEU RACE Race text RACE 1 DM.RACE RACEN Race (N) integer RACEN 1 Numeric code for RACE SEX Sex text SEX 1 DM.SEX ETHNIC Ethnicity text ETHNIC 1 DM.ETHNIC DTHFL Subject Died? text Y_BLANK 1 DM.DTHFL RFSTDTC Subject Reference Start Date/Time datetime ISO8601 1 DM.RFSTDTC RFENDTC Subject Reference End Date/Time datetime ISO8601 1 DM.RFENDTC SITEGR1 Pooled Site Group 1 text 2 refer to SAP, Section 7.1 - if not pooled then SITEGR1=SITEID. If pooled, SITEGR1 will be 900 TRTSDT Date of First Exposure to Treatment integer 2 SV.SVSTDTC when SV.VISITNUM=3, converted to SAS date TRTEDT Date of Last Exposure to Treatment integer 3 The date of final dose (from the CRF) is EX.EXENDTC on the subjects last EX record. If the date of final dose is missing for the subject and the subject discontinued after visit 3, use the date of discontinuation as the date of last dose. Convert the date to a SAS date. TRTDUR Duration of Treatment (days) integer 2 TRTEDT-TRTSDT+1 AVGDD Avg Daily Dose (as planned) float 2 CUMDOSE/TRTDUR CUMDOSE Cumulative Dose (as planned) float 3 For ARMN=0 or 1: CUMDOSE=TRT01PN*TRTDUR.  For ARMN=2: CUMDOSE will be based on 54mg per day for the # of days subj was in 1st dosing interval (i.e., visit4date-TRTSTDT+1 if 1st interval completed, TRTEDT-TRTSTDT+1 if subj discontinued &lt;=visit 4 and &gt; visit 3), 81mg per day for the # of days subj was in 2nd dosing interval (i.e., visit12date-visit4date if 2nd interval completed, TRTEDT-visit4date if subj discontinued &lt;= visit 12 and &gt; visit 4), and 54mg per day for the # of days subj was in 3rd dosing interval (i.e., TRTEDT - visit12date if subj continued after visit 12). AGEGR1 Pooled Age Group 1 text AGEGR1 2 Character variable derived from ADSL.AGEGR1N AGEGR1N Pooled Age Group 1 (N) integer AGEGR1N 2 AGEGR1 = 1 if AGE &lt;65. AGEGR1 = 2 if AGE 65-80. AGEGR1 = 3 if AGE &gt;80. SAFFL Safety Population Flag text YN 2 Y if ITTFL=Y and TRTSDT ne missing. N otherwise ITTFL Intent-To-Treat Population Flag text YN 2 Y if ARMCD ne  . N otherwise EFFFL Efficacy Population Flag text YN 3 Y if SAFFL=Y AND subject has at least one record in QS for ADAS-Cog with VISITNUM&gt;3 AND at least one record in QS for CIBIC+ with VISITNUM&gt;3, N otherwise COMP8FL Completers of Week 8 Population Flag text YN 2 Y if subject has a SV.VISITNUM=8 and ENDDT &gt;= date of visit 8, N otherwise COMP16FL Completers of Week 16 Population Flag text YN 2 Y if subject has a SV.VISITNUM=10 and ENDDT&gt;=date of visit 10, N otherwise COMP24FL Completers of Week 24 Population Flag text YN 2 Y if subject has a SV.VISITNUM=12 and ENDDT&gt;= date of visit 12 , N otherwise DISCONFL Did the Subject Discontinue the Study? text Y_BLANK 2 Y if DCREASCD ^= Completed. Null otherwise DSRAEFL Discontinued due to AE? text Y_BLANK 2 Y if DCREASCD=Adverse Event. Null otherwise BMIBL Baseline BMI (kg/m^2) float 2 WEIGHTBL / ((HEIGHTBL*100)**2) BMIBLGR1 Pooled Baseline BMI Group 1 text BMICAT 2 BMIBLGR1=Normal if . &lt; BMIBL &lt;25. BMIBLGR1=Overweight if 25 &lt;=BMIBL &lt;30. BMIBLGR1=Obese if BMIBL &gt;=30 HEIGHTBL Baseline Height (cm) float 2 VSSTRESN when VS.VSTESTCD=HEIGHT and VS.VISITNUM=1 WEIGHTBL Baseline Weight (kg) float 2 VSSTRESN when VS.VSTESTCD=WEIGHT and VS.VISITNUM=3 EDUCLVL Years of Education integer 2 SC.SCSTRESN where SC.SCTESTCD=YEARSEDU DISONSDT Date of Onset of Disease integer 2 MH.MHSTDTC where MHCAT=PRIMARY DIAGNOSIS converted to SAS date DURDIS Duration of Disease (Months) float 2 number of months between VISIT1DT and DISONSET DURDSGR1 Pooled Disease Duration Group 1 text DURDISC 2 grouping DURDIS values as &lt;12 and &gt;=12 VISIT1DT Date of Visit 1 integer 2 SV.SVSTDTC when SV.VISITNUM=1, converted to SAS date VISNUMEN End of Trt Visit (Vis 12 or Early Term.) integer 3 if DS.VISITNUM=13 where DSTERM=PROTCOL COMPLETED then VISNUMEN=12, otherwise VISNUMEN=DS.VISITNUM where DSTERM=PROTCOL COMPLETED RFENDT Date of Discontinuation/Completion integer 2 RFENDTC converted to SAS date DCDECOD Standardized Disposition Term text DISCCD 3 DS.DSDECOD where DSCAT=DISPOSITION EVENT DCREASCD Reason for Discontinuation text DISCREAS 2 Grouping of DCDECOD values to support summarizing study completion status and reason for discontinuation MMSETOT MMSE Total integer 2 sum of QS.QSORRES values for the subject "],["Variable.html", "7 Adsl derivations Derived = 1 level 7.1 Overview 7.2 Your Turn Lets start programming 7.3 Adsl Derivation Code part-1", " 7 Adsl derivations Derived = 1 level List of Variables Derived = 1 Variable Label Source/Derivation/Comments R Dplyr Snippet STUDYID Study Identifier DM.STUDYID select ( dm , studyid) USUBJID Unique Subject Identifier DM.USUBJID select ( dm , usubjid) SUBJID Subject Identifier for the Study DM.SUBJID select ( dm , subjid) SITEID Study Site Identifier DM.SITEID select ( dm , siteid) ARM Description of Planned Arm DM.ARM select ( dm , arm) TRT01P Planned Treatment for Period 01 DM.ARM select ( dm , arm) TRT01A Actual Treatment for Period 01 TRT01A=TRT01P, i.e., no difference between actual and randomized treatment in this study. mutate ( dm , TRT01A= ARM) TRT01AN Actual Treatment for Period 01 (N) Numeric code for TRT01A which corresponds to the randomized dose mutate( trt01pn =ifelse( (arm %in% \"Placebo\" ) , 0 , ifelse( (arm %in% Xanomeline Low Dose\" ) , 54, ifelse( (arm %in% \"Xanomeline High Dose\" ) , 81 , NA))) AGE Age DM.AGE select ( dm , age) RACE Race DM.RACE select ( dm , race) RACEN Race (N) Numeric code for RACE case_when( race %in% \"WHITE\" ~ 1 , race %in% \"BLACK OR AFRICAN AMERICAN\" ~ 2 , race %in% \"AMERICAN INDIAN OR ALASKA NATIVE\" ~ 6 , race %in% \"ASIAN\" ~ 7 ) SEX Sex DM.SEX select(dm,sex) ETHNIC Ethnicity DM.ETHNIC select(dm,ethnic) DTHFL Subject Died? DM.DTHFL select(dm,dthfl) RFSTDTC Subject Reference Start Date/Time DM.RFSTDTC select(dm,rfstdtc) RFENDTC Subject Reference End Date/Time DM.RFENDTC select(dm,rfendtc) 7.1 Overview 7.1.0.1 Important Functions dplyr is a grammar of data manipulation, providing a consistent set of verbs that help you solve the most common data manipulation challenges: mutate() adds new variables that are functions of existing variables select() picks variables based on their names. filter() picks cases based on their values. summarise() reduces multiple values down to a single summary. arrange() changes the ordering of the rows. 7.2 Your Turn **List out various Character and Numeric Dplyr functions** [Learn to use R Dplyr Package] List out all the functions for your Data manipulation Lets start programming Initialize all the Librarys needed for the project #intilizing the Dplyr library library(tidyverse) ## -- Attaching packages --------- tidyverse 1.3.0 -- ## v ggplot2 3.3.2 v purrr 0.3.4 ## v tibble 3.0.3 v dplyr 1.0.2 ## v tidyr 1.1.2 v stringr 1.4.0 ## v readr 1.3.1 v forcats 0.5.0 ## -- Conflicts ------------ tidyverse_conflicts() -- ## x dplyr::filter() masks stats::filter() ## x dplyr::lag() masks stats::lag() # dm &lt;- clinicalfd::dm names(clinicalfd::dm ) ## [1] &quot;studyid&quot; &quot;domain&quot; &quot;usubjid&quot; &quot;subjid&quot; &quot;rfstdtc&quot; &quot;rfendtc&quot; ## [7] &quot;rfxstdtc&quot; &quot;rfxendtc&quot; &quot;rficdtc&quot; &quot;rfpendtc&quot; &quot;dthdtc&quot; &quot;dthfl&quot; ## [13] &quot;siteid&quot; &quot;age&quot; &quot;ageu&quot; &quot;sex&quot; &quot;race&quot; &quot;ethnic&quot; ## [19] &quot;armcd&quot; &quot;arm&quot; &quot;actarmcd&quot; &quot;actarm&quot; &quot;country&quot; &quot;dmdtc&quot; ## [25] &quot;dmdy&quot; dm &lt;- clinicalfd::dm dm &lt;- dplyr :: filter(dm ,arm !=&quot;Screen Failure&quot; ) adsl_deri01 &lt;- dplyr::select ( dm , usubjid , siteid,arm) # Select #dm_01 &lt;- mutate (dm_01 , usubjid = as.character(usubjid) ) adsl_deri01 &lt;- dplyr::mutate( adsl_deri01 , TRT01P = arm) #Use of Mutate function to create new variable# 7.3 Adsl Derivation Code part-1 adsl_deri01 &lt;- dm %&gt;% filter (actarmcd !=&quot;Scrnfail&quot;) %&gt;% mutate(sitegr1 = siteid , trt01p = arm , trt01a = arm , trt01pn = ifelse( (arm %in% &quot;Placebo&quot; ) , 0 , ifelse( (arm %in% &quot;Xanomeline Low Dose&quot; ) , 54, ifelse( (arm %in% &quot;Xanomeline High Dose&quot; ) , 81 , NA))) , trt01an = trt01pn , ittfl = ifelse (trt01pn %in% c(0,54,81) , &quot;Y&quot; , &quot;N&quot; ), agegr1 = case_when( age &lt; 65 ~ &quot;&lt;65&quot; , (65 &lt;= age &amp; age &lt;= 80 ) ~ &quot;65-80&quot; , (age &gt; 80 ) ~ &quot;&gt;80&quot; ), agegr1n = case_when( age &lt; 65 ~ 1 , (65 &lt;= age &amp; age &lt;= 80 ) ~ 2 , (age &gt; 80 ) ~ 3 ), race = case_when( race %in% &quot;WHITE&quot; ~ &quot;WHITE&quot; , race %in% &quot;BLACK OR AFRICAN AMERICAN&quot; ~ &quot;BLACK OR AFRICAN AMERICAN&quot; , race %in% &quot;AMERICAN INDIAN OR ALASKA NATIVE&quot; ~ &quot;AMERICAN INDIAN OR ALASKA NATIVE&quot; , race %in% &quot;ASIAN&quot; ~ &quot;ASIAN&quot; ) , racen = case_when( race %in% &quot;WHITE&quot; ~ 1 , race %in% &quot;BLACK OR AFRICAN AMERICAN&quot; ~ 2 , race %in% &quot;AMERICAN INDIAN OR ALASKA NATIVE&quot; ~ 6 , race %in% &quot;ASIAN&quot; ~ 7 ), sex = case_when(sex %in% &quot;F&quot; ~ &quot;Female&quot; , sex %in% &quot;M&quot; ~ &quot;Male&quot; , sex %in% &quot;U&quot; ~ &quot;Unknown&quot; ) , ethnic = case_when(ethnic %in% &quot;NOT HISPANIC OR LATINO&quot; ~ &quot;NOT HISPANIC OR LATINO&quot; , ethnic %in% &quot;HISPANIC OR LATINO&quot; ~ &quot;HISPANIC OR LATINO&quot; , ethnic %in% &quot;U&quot; ~ &quot;Unknown&quot; ) ) adsl_deri02 &lt;- adsl_deri01 %&gt;% select (actarmcd , sitegr1, siteid , trt01p , arm , trt01a , trt01pn ,trt01pn,ittfl,agegr1,age,agegr1n,race,racen,sex,ethnic ) adsl_deri02 ## actarmcd sitegr1 siteid trt01p arm ## 1 Pbo 701 701 Placebo Placebo ## 2 Pbo 701 701 Placebo Placebo ## 3 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 4 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 5 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 6 Pbo 701 701 Placebo Placebo ## 7 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 8 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 9 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 10 Pbo 701 701 Placebo Placebo ## 11 Pbo 701 701 Placebo Placebo ## 12 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 13 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 14 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 15 Pbo 701 701 Placebo Placebo ## 16 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 17 Xan_Lo 701 701 Xanomeline High Dose Xanomeline High Dose ## 18 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 19 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 20 Pbo 701 701 Placebo Placebo ## 21 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 22 Pbo 701 701 Placebo Placebo ## 23 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 24 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 25 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 26 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 27 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 28 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 29 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 30 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 31 Pbo 701 701 Placebo Placebo ## 32 Xan_Lo 701 701 Xanomeline High Dose Xanomeline High Dose ## 33 Pbo 701 701 Placebo Placebo ## 34 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 35 Pbo 701 701 Placebo Placebo ## 36 Pbo 701 701 Placebo Placebo ## 37 Pbo 701 701 Placebo Placebo ## 38 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 39 Pbo 701 701 Placebo Placebo ## 40 Xan_Lo 701 701 Xanomeline Low Dose Xanomeline Low Dose ## 41 Xan_Hi 701 701 Xanomeline High Dose Xanomeline High Dose ## 42 Xan_Lo 702 702 Xanomeline Low Dose Xanomeline Low Dose ## 43 Pbo 703 703 Placebo Placebo ## 44 Xan_Hi 703 703 Xanomeline High Dose Xanomeline High Dose ## 45 Xan_Lo 703 703 Xanomeline Low Dose Xanomeline Low Dose ## 46 Pbo 703 703 Placebo Placebo ## 47 Pbo 703 703 Placebo Placebo ## 48 Xan_Lo 703 703 Xanomeline Low Dose Xanomeline Low Dose ## 49 Pbo 703 703 Placebo Placebo ## 50 Xan_Lo 703 703 Xanomeline Low Dose Xanomeline Low Dose ## 51 Xan_Lo 703 703 Xanomeline Low Dose Xanomeline Low Dose ## 52 Pbo 703 703 Placebo Placebo ## 53 Xan_Hi 703 703 Xanomeline High Dose Xanomeline High Dose ## 54 Xan_Lo 703 703 Xanomeline Low Dose Xanomeline Low Dose ## 55 Xan_Hi 703 703 Xanomeline High Dose Xanomeline High Dose ## 56 Pbo 703 703 Placebo Placebo ## 57 Xan_Hi 703 703 Xanomeline High Dose Xanomeline High Dose ## 58 Xan_Lo 703 703 Xanomeline Low Dose Xanomeline Low Dose ## 59 Xan_Lo 703 703 Xanomeline High Dose Xanomeline High Dose ## 60 Xan_Hi 703 703 Xanomeline High Dose Xanomeline High Dose ## 61 Xan_Hi 704 704 Xanomeline High Dose Xanomeline High Dose ## 62 Xan_Lo 704 704 Xanomeline Low Dose Xanomeline Low Dose ## 63 Pbo 704 704 Placebo Placebo ## 64 Xan_Hi 704 704 Xanomeline High Dose Xanomeline High Dose ## 65 Xan_Lo 704 704 Xanomeline Low Dose Xanomeline Low Dose ## 66 Xan_Hi 704 704 Xanomeline High Dose Xanomeline High Dose ## 67 Xan_Hi 704 704 Xanomeline High Dose Xanomeline High Dose ## 68 Xan_Hi 704 704 Xanomeline High Dose Xanomeline High Dose ## 69 Xan_Lo 704 704 Xanomeline Low Dose Xanomeline Low Dose ## 70 Xan_Lo 704 704 Xanomeline Low Dose Xanomeline Low Dose ## 71 Pbo 704 704 Placebo Placebo ## 72 Xan_Lo 704 704 Xanomeline Low Dose Xanomeline Low Dose ## 73 Pbo 704 704 Placebo Placebo ## 74 Xan_Lo 704 704 Xanomeline Low Dose Xanomeline Low Dose ## 75 Pbo 704 704 Placebo Placebo ## 76 Xan_Hi 704 704 Xanomeline High Dose Xanomeline High Dose ## 77 Pbo 704 704 Placebo Placebo ## 78 Xan_Hi 704 704 Xanomeline High Dose Xanomeline High Dose ## 79 Xan_Lo 704 704 Xanomeline Low Dose Xanomeline Low Dose ## 80 Xan_Lo 704 704 Xanomeline Low Dose Xanomeline Low Dose ## 81 Xan_Hi 704 704 Xanomeline High Dose Xanomeline High Dose ## 82 Pbo 704 704 Placebo Placebo ## 83 Pbo 704 704 Placebo Placebo ## 84 Pbo 704 704 Placebo Placebo ## 85 Pbo 704 704 Placebo Placebo ## 86 Pbo 705 705 Placebo Placebo ## 87 Xan_Lo 705 705 Xanomeline Low Dose Xanomeline Low Dose ## 88 Pbo 705 705 Placebo Placebo ## 89 Pbo 705 705 Placebo Placebo ## 90 Xan_Lo 705 705 Xanomeline Low Dose Xanomeline Low Dose ## 91 Xan_Hi 705 705 Xanomeline High Dose Xanomeline High Dose ## 92 Xan_Hi 705 705 Xanomeline High Dose Xanomeline High Dose ## 93 Pbo 705 705 Placebo Placebo ## 94 Xan_Lo 705 705 Xanomeline Low Dose Xanomeline Low Dose ## 95 Xan_Hi 705 705 Xanomeline High Dose Xanomeline High Dose ## 96 Xan_Hi 705 705 Xanomeline High Dose Xanomeline High Dose ## 97 Pbo 705 705 Placebo Placebo ## 98 Xan_Hi 705 705 Xanomeline High Dose Xanomeline High Dose ## 99 Xan_Lo 705 705 Xanomeline High Dose Xanomeline High Dose ## 100 Xan_Lo 705 705 Xanomeline Low Dose Xanomeline Low Dose ## 101 Xan_Lo 705 705 Xanomeline Low Dose Xanomeline Low Dose ## 102 Pbo 706 706 Placebo Placebo ## 103 Xan_Hi 706 706 Xanomeline High Dose Xanomeline High Dose ## 104 Xan_Lo 706 706 Xanomeline Low Dose Xanomeline Low Dose ## 105 Xan_Lo 707 707 Xanomeline Low Dose Xanomeline Low Dose ## 106 Pbo 707 707 Placebo Placebo ## 107 Xan_Lo 708 708 Xanomeline Low Dose Xanomeline Low Dose ## 108 Xan_Lo 708 708 Xanomeline Low Dose Xanomeline Low Dose ## 109 Xan_Lo 708 708 Xanomeline Low Dose Xanomeline Low Dose ## 110 Pbo 708 708 Placebo Placebo ## 111 Pbo 708 708 Placebo Placebo ## 112 Pbo 708 708 Placebo Placebo ## 113 Xan_Hi 708 708 Xanomeline High Dose Xanomeline High Dose ## 114 Xan_Lo 708 708 Xanomeline High Dose Xanomeline High Dose ## 115 Xan_Hi 708 708 Xanomeline High Dose Xanomeline High Dose ## 116 Xan_Lo 708 708 Xanomeline High Dose Xanomeline High Dose ## 117 Pbo 708 708 Placebo Placebo ## 118 Xan_Lo 708 708 Xanomeline Low Dose Xanomeline Low Dose ## 119 Pbo 708 708 Placebo Placebo ## 120 Pbo 708 708 Placebo Placebo ## 121 Xan_Lo 708 708 Xanomeline Low Dose Xanomeline Low Dose ## 122 Pbo 708 708 Placebo Placebo ## 123 Xan_Hi 708 708 Xanomeline High Dose Xanomeline High Dose ## 124 Pbo 708 708 Placebo Placebo ## 125 Xan_Hi 708 708 Xanomeline High Dose Xanomeline High Dose ## 126 Xan_Lo 708 708 Xanomeline Low Dose Xanomeline Low Dose ## 127 Xan_Lo 708 708 Xanomeline Low Dose Xanomeline Low Dose ## 128 Xan_Lo 708 708 Xanomeline High Dose Xanomeline High Dose ## 129 Pbo 708 708 Placebo Placebo ## 130 Xan_Hi 708 708 Xanomeline High Dose Xanomeline High Dose ## 131 Xan_Lo 708 708 Xanomeline Low Dose Xanomeline Low Dose ## 132 Pbo 709 709 Placebo Placebo ## 133 Xan_Lo 709 709 Xanomeline Low Dose Xanomeline Low Dose ## 134 Xan_Lo 709 709 Xanomeline Low Dose Xanomeline Low Dose ## 135 Xan_Hi 709 709 Xanomeline High Dose Xanomeline High Dose ## 136 Xan_Lo 709 709 Xanomeline Low Dose Xanomeline Low Dose ## 137 Pbo 709 709 Placebo Placebo ## 138 Xan_Hi 709 709 Xanomeline High Dose Xanomeline High Dose ## 139 Xan_Lo 709 709 Xanomeline Low Dose Xanomeline Low Dose ## 140 Xan_Hi 709 709 Xanomeline High Dose Xanomeline High Dose ## 141 Xan_Lo 709 709 Xanomeline Low Dose Xanomeline Low Dose ## 142 Xan_Hi 709 709 Xanomeline High Dose Xanomeline High Dose ## 143 Pbo 709 709 Placebo Placebo ## 144 Xan_Lo 709 709 Xanomeline Low Dose Xanomeline Low Dose ## 145 Pbo 709 709 Placebo Placebo ## 146 Pbo 709 709 Placebo Placebo ## 147 Xan_Hi 709 709 Xanomeline High Dose Xanomeline High Dose ## 148 Pbo 709 709 Placebo Placebo ## 149 Xan_Lo 709 709 Xanomeline Low Dose Xanomeline Low Dose ## 150 Xan_Lo 709 709 Xanomeline High Dose Xanomeline High Dose ## 151 Pbo 709 709 Placebo Placebo ## 152 Xan_Lo 709 709 Xanomeline High Dose Xanomeline High Dose ## 153 Xan_Lo 710 710 Xanomeline Low Dose Xanomeline Low Dose ## 154 Xan_Hi 710 710 Xanomeline High Dose Xanomeline High Dose ## 155 Xan_Hi 710 710 Xanomeline High Dose Xanomeline High Dose ## 156 Pbo 710 710 Placebo Placebo ## 157 Xan_Lo 710 710 Xanomeline Low Dose Xanomeline Low Dose ## 158 Xan_Lo 710 710 Xanomeline Low Dose Xanomeline Low Dose ## 159 Pbo 710 710 Placebo Placebo ## 160 Xan_Hi 710 710 Xanomeline High Dose Xanomeline High Dose ## 161 Pbo 710 710 Placebo Placebo ## 162 Pbo 710 710 Placebo Placebo ## 163 Pbo 710 710 Placebo Placebo ## 164 Xan_Hi 710 710 Xanomeline High Dose Xanomeline High Dose ## 165 Xan_Hi 710 710 Xanomeline High Dose Xanomeline High Dose ## 166 Xan_Lo 710 710 Xanomeline Low Dose Xanomeline Low Dose ## 167 Xan_Lo 710 710 Xanomeline Low Dose Xanomeline Low Dose ## 168 Pbo 710 710 Placebo Placebo ## 169 Xan_Hi 710 710 Xanomeline High Dose Xanomeline High Dose ## 170 Xan_Lo 710 710 Xanomeline Low Dose Xanomeline Low Dose ## 171 Xan_Hi 710 710 Xanomeline High Dose Xanomeline High Dose ## 172 Pbo 710 710 Placebo Placebo ## 173 Xan_Lo 710 710 Xanomeline Low Dose Xanomeline Low Dose ## 174 Pbo 710 710 Placebo Placebo ## 175 Xan_Hi 710 710 Xanomeline High Dose Xanomeline High Dose ## 176 Xan_Lo 710 710 Xanomeline Low Dose Xanomeline Low Dose ## 177 Pbo 710 710 Placebo Placebo ## 178 Pbo 710 710 Placebo Placebo ## 179 Xan_Hi 710 710 Xanomeline High Dose Xanomeline High Dose ## 180 Xan_Lo 710 710 Xanomeline Low Dose Xanomeline Low Dose ## 181 Pbo 710 710 Placebo Placebo ## 182 Xan_Lo 710 710 Xanomeline Low Dose Xanomeline Low Dose ## 183 Xan_Hi 710 710 Xanomeline High Dose Xanomeline High Dose ## 184 Xan_Hi 711 711 Xanomeline High Dose Xanomeline High Dose ## 185 Pbo 711 711 Placebo Placebo ## 186 Xan_Lo 711 711 Xanomeline Low Dose Xanomeline Low Dose ## 187 Xan_Lo 711 711 Xanomeline High Dose Xanomeline High Dose ## 188 Xan_Lo 713 713 Xanomeline Low Dose Xanomeline Low Dose ## 189 Xan_Lo 713 713 Xanomeline Low Dose Xanomeline Low Dose ## 190 Xan_Hi 713 713 Xanomeline High Dose Xanomeline High Dose ## 191 Xan_Hi 713 713 Xanomeline High Dose Xanomeline High Dose ## 192 Pbo 713 713 Placebo Placebo ## 193 Xan_Hi 713 713 Xanomeline High Dose Xanomeline High Dose ## 194 Pbo 713 713 Placebo Placebo ## 195 Pbo 713 713 Placebo Placebo ## 196 Xan_Lo 713 713 Xanomeline Low Dose Xanomeline Low Dose ## 197 Pbo 714 714 Placebo Placebo ## 198 Xan_Lo 714 714 Xanomeline Low Dose Xanomeline Low Dose ## 199 Xan_Lo 714 714 Xanomeline Low Dose Xanomeline Low Dose ## 200 Xan_Hi 714 714 Xanomeline High Dose Xanomeline High Dose ## 201 Pbo 714 714 Placebo Placebo ## 202 Xan_Lo 714 714 Xanomeline High Dose Xanomeline High Dose ## 203 Xan_Lo 715 715 Xanomeline Low Dose Xanomeline Low Dose ## 204 Xan_Lo 715 715 Xanomeline Low Dose Xanomeline Low Dose ## 205 Pbo 715 715 Placebo Placebo ## 206 Pbo 715 715 Placebo Placebo ## 207 Xan_Hi 715 715 Xanomeline High Dose Xanomeline High Dose ## 208 Xan_Hi 715 715 Xanomeline High Dose Xanomeline High Dose ## 209 Pbo 715 715 Placebo Placebo ## 210 Xan_Lo 715 715 Xanomeline Low Dose Xanomeline Low Dose ## 211 Pbo 716 716 Placebo Placebo ## 212 Pbo 716 716 Placebo Placebo ## 213 Xan_Lo 716 716 Xanomeline High Dose Xanomeline High Dose ## 214 Pbo 716 716 Placebo Placebo ## 215 Xan_Lo 716 716 Xanomeline Low Dose Xanomeline Low Dose ## 216 Xan_Hi 716 716 Xanomeline High Dose Xanomeline High Dose ## 217 Xan_Lo 716 716 Xanomeline Low Dose Xanomeline Low Dose ## 218 Xan_Lo 716 716 Xanomeline Low Dose Xanomeline Low Dose ## 219 Pbo 716 716 Placebo Placebo ## 220 Xan_Lo 716 716 Xanomeline Low Dose Xanomeline Low Dose ## 221 Xan_Lo 716 716 Xanomeline Low Dose Xanomeline Low Dose ## 222 Pbo 716 716 Placebo Placebo ## 223 Xan_Lo 716 716 Xanomeline Low Dose Xanomeline Low Dose ## 224 Pbo 716 716 Placebo Placebo ## 225 Xan_Hi 716 716 Xanomeline High Dose Xanomeline High Dose ## 226 Xan_Hi 716 716 Xanomeline High Dose Xanomeline High Dose ## 227 Xan_Lo 716 716 Xanomeline Low Dose Xanomeline Low Dose ## 228 Pbo 716 716 Placebo Placebo ## 229 Xan_Lo 716 716 Xanomeline Low Dose Xanomeline Low Dose ## 230 Xan_Hi 716 716 Xanomeline High Dose Xanomeline High Dose ## 231 Xan_Hi 716 716 Xanomeline High Dose Xanomeline High Dose ## 232 Xan_Hi 716 716 Xanomeline High Dose Xanomeline High Dose ## 233 Pbo 716 716 Placebo Placebo ## 234 Xan_Hi 716 716 Xanomeline High Dose Xanomeline High Dose ## 235 Xan_Lo 717 717 Xanomeline Low Dose Xanomeline Low Dose ## 236 Xan_Hi 717 717 Xanomeline High Dose Xanomeline High Dose ## 237 Xan_Hi 717 717 Xanomeline High Dose Xanomeline High Dose ## 238 Pbo 717 717 Placebo Placebo ## 239 Pbo 717 717 Placebo Placebo ## 240 Xan_Hi 717 717 Xanomeline High Dose Xanomeline High Dose ## 241 Xan_Lo 717 717 Xanomeline Low Dose Xanomeline Low Dose ## 242 Xan_Lo 718 718 Xanomeline Low Dose Xanomeline Low Dose ## 243 Xan_Lo 718 718 Xanomeline Low Dose Xanomeline Low Dose ## 244 Xan_Hi 718 718 Xanomeline High Dose Xanomeline High Dose ## 245 Pbo 718 718 Placebo Placebo ## 246 Pbo 718 718 Placebo Placebo ## 247 Xan_Lo 718 718 Xanomeline Low Dose Xanomeline Low Dose ## 248 Pbo 718 718 Placebo Placebo ## 249 Xan_Lo 718 718 Xanomeline Low Dose Xanomeline Low Dose ## 250 Xan_Lo 718 718 Xanomeline Low Dose Xanomeline Low Dose ## 251 Xan_Hi 718 718 Xanomeline High Dose Xanomeline High Dose ## 252 Pbo 718 718 Placebo Placebo ## 253 Xan_Hi 718 718 Xanomeline High Dose Xanomeline High Dose ## 254 Xan_Hi 718 718 Xanomeline High Dose Xanomeline High Dose ## trt01a trt01pn ittfl agegr1 age agegr1n ## 1 Placebo 0 Y &lt;65 63 1 ## 2 Placebo 0 Y &lt;65 64 1 ## 3 Xanomeline High Dose 81 Y 65-80 71 2 ## 4 Xanomeline Low Dose 54 Y 65-80 74 2 ## 5 Xanomeline High Dose 81 Y 65-80 77 2 ## 6 Placebo 0 Y &gt;80 85 3 ## 7 Xanomeline Low Dose 54 Y 65-80 68 2 ## 8 Xanomeline Low Dose 54 Y &gt;80 81 3 ## 9 Xanomeline Low Dose 54 Y &gt;80 84 3 ## 10 Placebo 0 Y &lt;65 52 1 ## 11 Placebo 0 Y &gt;80 84 3 ## 12 Xanomeline High Dose 81 Y &gt;80 81 3 ## 13 Xanomeline High Dose 81 Y 65-80 75 2 ## 14 Xanomeline High Dose 81 Y &lt;65 57 1 ## 15 Placebo 0 Y 65-80 79 2 ## 16 Xanomeline High Dose 81 Y &lt;65 56 1 ## 17 Xanomeline High Dose 81 Y 65-80 79 2 ## 18 Xanomeline Low Dose 54 Y 65-80 71 2 ## 19 Xanomeline Low Dose 54 Y 65-80 80 2 ## 20 Placebo 0 Y &gt;80 81 3 ## 21 Xanomeline Low Dose 54 Y 65-80 76 2 ## 22 Placebo 0 Y 65-80 69 2 ## 23 Xanomeline High Dose 81 Y &lt;65 56 1 ## 24 Xanomeline High Dose 81 Y &lt;65 61 1 ## 25 Xanomeline High Dose 81 Y &lt;65 56 1 ## 26 Xanomeline Low Dose 54 Y 65-80 67 2 ## 27 Xanomeline High Dose 81 Y &lt;65 61 1 ## 28 Xanomeline Low Dose 54 Y 65-80 68 2 ## 29 Xanomeline Low Dose 54 Y 65-80 79 2 ## 30 Xanomeline Low Dose 54 Y &lt;65 51 1 ## 31 Placebo 0 Y &lt;65 63 1 ## 32 Xanomeline High Dose 81 Y 65-80 67 2 ## 33 Placebo 0 Y &gt;80 81 3 ## 34 Xanomeline High Dose 81 Y 65-80 72 2 ## 35 Placebo 0 Y &gt;80 87 3 ## 36 Placebo 0 Y 65-80 78 2 ## 37 Placebo 0 Y &gt;80 85 3 ## 38 Xanomeline Low Dose 54 Y &gt;80 84 3 ## 39 Placebo 0 Y 65-80 70 2 ## 40 Xanomeline Low Dose 54 Y &lt;65 57 1 ## 41 Xanomeline High Dose 81 Y &lt;65 63 1 ## 42 Xanomeline Low Dose 54 Y &gt;80 84 3 ## 43 Placebo 0 Y &lt;65 64 1 ## 44 Xanomeline High Dose 81 Y 65-80 69 2 ## 45 Xanomeline Low Dose 54 Y 65-80 71 2 ## 46 Placebo 0 Y &gt;80 81 3 ## 47 Placebo 0 Y &gt;80 84 3 ## 48 Xanomeline Low Dose 54 Y &gt;80 81 3 ## 49 Placebo 0 Y 65-80 75 2 ## 50 Xanomeline Low Dose 54 Y &gt;80 84 3 ## 51 Xanomeline Low Dose 54 Y 65-80 76 2 ## 52 Placebo 0 Y 65-80 72 2 ## 53 Xanomeline High Dose 81 Y 65-80 78 2 ## 54 Xanomeline Low Dose 54 Y 65-80 72 2 ## 55 Xanomeline High Dose 81 Y &gt;80 88 3 ## 56 Placebo 0 Y &gt;80 81 3 ## 57 Xanomeline High Dose 81 Y 65-80 67 2 ## 58 Xanomeline Low Dose 54 Y &gt;80 81 3 ## 59 Xanomeline High Dose 81 Y 65-80 67 2 ## 60 Xanomeline High Dose 81 Y 65-80 76 2 ## 61 Xanomeline High Dose 81 Y 65-80 76 2 ## 62 Xanomeline Low Dose 54 Y &gt;80 83 3 ## 63 Placebo 0 Y 65-80 80 2 ## 64 Xanomeline High Dose 81 Y 65-80 77 2 ## 65 Xanomeline Low Dose 54 Y &gt;80 81 3 ## 66 Xanomeline High Dose 81 Y 65-80 75 2 ## 67 Xanomeline High Dose 81 Y 65-80 80 2 ## 68 Xanomeline High Dose 81 Y 65-80 79 2 ## 69 Xanomeline Low Dose 54 Y 65-80 77 2 ## 70 Xanomeline Low Dose 54 Y 65-80 71 2 ## 71 Placebo 0 Y &gt;80 84 3 ## 72 Xanomeline Low Dose 54 Y 65-80 74 2 ## 73 Placebo 0 Y 65-80 67 2 ## 74 Xanomeline Low Dose 54 Y &gt;80 81 3 ## 75 Placebo 0 Y &gt;80 87 3 ## 76 Xanomeline High Dose 81 Y &gt;80 86 3 ## 77 Placebo 0 Y 65-80 71 2 ## 78 Xanomeline High Dose 81 Y &gt;80 82 3 ## 79 Xanomeline Low Dose 54 Y 65-80 68 2 ## 80 Xanomeline Low Dose 54 Y &gt;80 81 3 ## 81 Xanomeline High Dose 81 Y 65-80 80 2 ## 82 Placebo 0 Y 65-80 70 2 ## 83 Placebo 0 Y &gt;80 81 3 ## 84 Placebo 0 Y 65-80 74 2 ## 85 Placebo 0 Y 65-80 75 2 ## 86 Placebo 0 Y 65-80 69 2 ## 87 Xanomeline Low Dose 54 Y &lt;65 56 1 ## 88 Placebo 0 Y 65-80 66 2 ## 89 Placebo 0 Y &gt;80 84 3 ## 90 Xanomeline Low Dose 54 Y &gt;80 87 3 ## 91 Xanomeline High Dose 81 Y &lt;65 56 1 ## 92 Xanomeline High Dose 81 Y 65-80 73 2 ## 93 Placebo 0 Y 65-80 70 2 ## 94 Xanomeline Low Dose 54 Y &lt;65 60 1 ## 95 Xanomeline High Dose 81 Y 65-80 72 2 ## 96 Xanomeline High Dose 81 Y 65-80 74 2 ## 97 Placebo 0 Y &gt;80 86 3 ## 98 Xanomeline High Dose 81 Y &lt;65 63 1 ## 99 Xanomeline High Dose 81 Y &gt;80 82 3 ## 100 Xanomeline Low Dose 54 Y &gt;80 84 3 ## 101 Xanomeline Low Dose 54 Y 65-80 68 2 ## 102 Placebo 0 Y &lt;65 64 1 ## 103 Xanomeline High Dose 81 Y &lt;65 60 1 ## 104 Xanomeline Low Dose 54 Y 65-80 74 2 ## 105 Xanomeline Low Dose 54 Y 65-80 72 2 ## 106 Placebo 0 Y 65-80 65 2 ## 107 Xanomeline Low Dose 54 Y 65-80 68 2 ## 108 Xanomeline Low Dose 54 Y &lt;65 62 1 ## 109 Xanomeline Low Dose 54 Y 65-80 73 2 ## 110 Placebo 0 Y 65-80 74 2 ## 111 Placebo 0 Y &gt;80 81 3 ## 112 Placebo 0 Y 65-80 77 2 ## 113 Xanomeline High Dose 81 Y 65-80 77 2 ## 114 Xanomeline High Dose 81 Y 65-80 76 2 ## 115 Xanomeline High Dose 81 Y 65-80 78 2 ## 116 Xanomeline High Dose 81 Y &gt;80 86 3 ## 117 Placebo 0 Y &lt;65 61 1 ## 118 Xanomeline Low Dose 54 Y &gt;80 82 3 ## 119 Placebo 0 Y 65-80 80 2 ## 120 Placebo 0 Y &lt;65 57 1 ## 121 Xanomeline Low Dose 54 Y &lt;65 61 1 ## 122 Placebo 0 Y 65-80 74 2 ## 123 Xanomeline High Dose 81 Y 65-80 73 2 ## 124 Placebo 0 Y &lt;65 59 1 ## 125 Xanomeline High Dose 81 Y &lt;65 61 1 ## 126 Xanomeline Low Dose 54 Y 65-80 79 2 ## 127 Xanomeline Low Dose 54 Y &gt;80 87 3 ## 128 Xanomeline High Dose 81 Y &gt;80 84 3 ## 129 Placebo 0 Y 65-80 67 2 ## 130 Xanomeline High Dose 81 Y 65-80 71 2 ## 131 Xanomeline Low Dose 54 Y &gt;80 84 3 ## 132 Placebo 0 Y 65-80 76 2 ## 133 Xanomeline Low Dose 54 Y &lt;65 54 1 ## 134 Xanomeline Low Dose 54 Y 65-80 72 2 ## 135 Xanomeline High Dose 81 Y &gt;80 82 3 ## 136 Xanomeline Low Dose 54 Y &gt;80 86 3 ## 137 Placebo 0 Y 65-80 69 2 ## 138 Xanomeline High Dose 81 Y 65-80 79 2 ## 139 Xanomeline Low Dose 54 Y 65-80 71 2 ## 140 Xanomeline High Dose 81 Y 65-80 72 2 ## 141 Xanomeline Low Dose 54 Y 65-80 77 2 ## 142 Xanomeline High Dose 81 Y 65-80 69 2 ## 143 Placebo 0 Y &gt;80 82 3 ## 144 Xanomeline Low Dose 54 Y &gt;80 87 3 ## 145 Placebo 0 Y &lt;65 62 1 ## 146 Placebo 0 Y &lt;65 60 1 ## 147 Xanomeline High Dose 81 Y 65-80 65 2 ## 148 Placebo 0 Y 65-80 68 2 ## 149 Xanomeline Low Dose 54 Y 65-80 75 2 ## 150 Xanomeline High Dose 81 Y 65-80 70 2 ## 151 Placebo 0 Y &gt;80 81 3 ## 152 Xanomeline High Dose 81 Y 65-80 77 2 ## 153 Xanomeline Low Dose 54 Y &gt;80 88 3 ## 154 Xanomeline High Dose 81 Y 65-80 77 2 ## 155 Xanomeline High Dose 81 Y 65-80 79 2 ## 156 Placebo 0 Y &gt;80 83 3 ## 157 Xanomeline Low Dose 54 Y &gt;80 83 3 ## 158 Xanomeline Low Dose 54 Y &gt;80 84 3 ## 159 Placebo 0 Y &gt;80 82 3 ## 160 Xanomeline High Dose 81 Y &gt;80 85 3 ## 161 Placebo 0 Y 65-80 76 2 ## 162 Placebo 0 Y &gt;80 81 3 ## 163 Placebo 0 Y &gt;80 89 3 ## 164 Xanomeline High Dose 81 Y 65-80 79 2 ## 165 Xanomeline High Dose 81 Y 65-80 76 2 ## 166 Xanomeline Low Dose 54 Y &gt;80 84 3 ## 167 Xanomeline Low Dose 54 Y &gt;80 81 3 ## 168 Placebo 0 Y 65-80 80 2 ## 169 Xanomeline High Dose 81 Y 65-80 78 2 ## 170 Xanomeline Low Dose 54 Y &lt;65 56 1 ## 171 Xanomeline High Dose 81 Y 65-80 79 2 ## 172 Placebo 0 Y 65-80 78 2 ## 173 Xanomeline Low Dose 54 Y &gt;80 83 3 ## 174 Placebo 0 Y &gt;80 86 3 ## 175 Xanomeline High Dose 81 Y &gt;80 81 3 ## 176 Xanomeline Low Dose 54 Y 65-80 78 2 ## 177 Placebo 0 Y 65-80 78 2 ## 178 Placebo 0 Y &gt;80 83 3 ## 179 Xanomeline High Dose 81 Y 65-80 73 2 ## 180 Xanomeline Low Dose 54 Y &gt;80 82 3 ## 181 Placebo 0 Y &gt;80 88 3 ## 182 Xanomeline Low Dose 54 Y 65-80 77 2 ## 183 Xanomeline High Dose 81 Y 65-80 80 2 ## 184 Xanomeline High Dose 81 Y 65-80 67 2 ## 185 Placebo 0 Y 65-80 70 2 ## 186 Xanomeline Low Dose 54 Y 65-80 76 2 ## 187 Xanomeline High Dose 81 Y &gt;80 84 3 ## 188 Xanomeline Low Dose 54 Y 65-80 78 2 ## 189 Xanomeline Low Dose 54 Y 65-80 74 2 ## 190 Xanomeline High Dose 81 Y 65-80 74 2 ## 191 Xanomeline High Dose 81 Y 65-80 79 2 ## 192 Placebo 0 Y &lt;65 64 1 ## 193 Xanomeline High Dose 81 Y 65-80 77 2 ## 194 Placebo 0 Y 65-80 71 2 ## 195 Placebo 0 Y 65-80 73 2 ## 196 Xanomeline Low Dose 54 Y 65-80 71 2 ## 197 Placebo 0 Y &gt;80 88 3 ## 198 Xanomeline Low Dose 54 Y 65-80 79 2 ## 199 Xanomeline Low Dose 54 Y 65-80 75 2 ## 200 Xanomeline High Dose 81 Y 65-80 77 2 ## 201 Placebo 0 Y 65-80 78 2 ## 202 Xanomeline High Dose 81 Y &gt;80 81 3 ## 203 Xanomeline Low Dose 54 Y 65-80 77 2 ## 204 Xanomeline Low Dose 54 Y 65-80 65 2 ## 205 Placebo 0 Y &lt;65 59 1 ## 206 Placebo 0 Y 65-80 78 2 ## 207 Xanomeline High Dose 81 Y 65-80 65 2 ## 208 Xanomeline High Dose 81 Y 65-80 75 2 ## 209 Placebo 0 Y 65-80 76 2 ## 210 Xanomeline Low Dose 54 Y 65-80 69 2 ## 211 Placebo 0 Y &gt;80 87 3 ## 212 Placebo 0 Y 65-80 73 2 ## 213 Xanomeline High Dose 81 Y &gt;80 83 3 ## 214 Placebo 0 Y 65-80 74 2 ## 215 Xanomeline Low Dose 54 Y 65-80 80 2 ## 216 Xanomeline High Dose 81 Y 65-80 78 2 ## 217 Xanomeline Low Dose 54 Y &gt;80 82 3 ## 218 Xanomeline Low Dose 54 Y 65-80 79 2 ## 219 Placebo 0 Y &gt;80 86 3 ## 220 Xanomeline Low Dose 54 Y &gt;80 83 3 ## 221 Xanomeline Low Dose 54 Y &gt;80 85 3 ## 222 Placebo 0 Y &gt;80 83 3 ## 223 Xanomeline Low Dose 54 Y 65-80 68 2 ## 224 Placebo 0 Y 65-80 72 2 ## 225 Xanomeline High Dose 81 Y &gt;80 81 3 ## 226 Xanomeline High Dose 81 Y 65-80 73 2 ## 227 Xanomeline Low Dose 54 Y 65-80 76 2 ## 228 Placebo 0 Y 65-80 76 2 ## 229 Xanomeline Low Dose 54 Y 65-80 78 2 ## 230 Xanomeline High Dose 81 Y &gt;80 84 3 ## 231 Xanomeline High Dose 81 Y 65-80 74 2 ## 232 Xanomeline High Dose 81 Y 65-80 80 2 ## 233 Placebo 0 Y &gt;80 85 3 ## 234 Xanomeline High Dose 81 Y 65-80 72 2 ## 235 Xanomeline Low Dose 54 Y 65-80 80 2 ## 236 Xanomeline High Dose 81 Y &gt;80 84 3 ## 237 Xanomeline High Dose 81 Y 65-80 73 2 ## 238 Placebo 0 Y &gt;80 85 3 ## 239 Placebo 0 Y &lt;65 64 1 ## 240 Xanomeline High Dose 81 Y 65-80 77 2 ## 241 Xanomeline Low Dose 54 Y 65-80 75 2 ## 242 Xanomeline Low Dose 54 Y 65-80 79 2 ## 243 Xanomeline Low Dose 54 Y 65-80 67 2 ## 244 Xanomeline High Dose 81 Y &gt;80 82 3 ## 245 Placebo 0 Y 65-80 77 2 ## 246 Placebo 0 Y 65-80 73 2 ## 247 Xanomeline Low Dose 54 Y 65-80 80 2 ## 248 Placebo 0 Y 65-80 74 2 ## 249 Xanomeline Low Dose 54 Y &gt;80 82 3 ## 250 Xanomeline Low Dose 54 Y 65-80 78 2 ## 251 Xanomeline High Dose 81 Y &gt;80 86 3 ## 252 Placebo 0 Y 65-80 79 2 ## 253 Xanomeline High Dose 81 Y 65-80 69 2 ## 254 Xanomeline High Dose 81 Y 65-80 74 2 ## race racen sex ethnic ## 1 WHITE 1 Female HISPANIC OR LATINO ## 2 WHITE 1 Male HISPANIC OR LATINO ## 3 WHITE 1 Male NOT HISPANIC OR LATINO ## 4 WHITE 1 Male NOT HISPANIC OR LATINO ## 5 WHITE 1 Female NOT HISPANIC OR LATINO ## 6 WHITE 1 Female NOT HISPANIC OR LATINO ## 7 WHITE 1 Male NOT HISPANIC OR LATINO ## 8 WHITE 1 Female NOT HISPANIC OR LATINO ## 9 WHITE 1 Male NOT HISPANIC OR LATINO ## 10 WHITE 1 Male NOT HISPANIC OR LATINO ## 11 WHITE 1 Male NOT HISPANIC OR LATINO ## 12 WHITE 1 Female NOT HISPANIC OR LATINO ## 13 WHITE 1 Female NOT HISPANIC OR LATINO ## 14 WHITE 1 Male NOT HISPANIC OR LATINO ## 15 WHITE 1 Female NOT HISPANIC OR LATINO ## 16 WHITE 1 Male NOT HISPANIC OR LATINO ## 17 WHITE 1 Female NOT HISPANIC OR LATINO ## 18 WHITE 1 Male NOT HISPANIC OR LATINO ## 19 WHITE 1 Female NOT HISPANIC OR LATINO ## 20 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 21 WHITE 1 Female NOT HISPANIC OR LATINO ## 22 WHITE 1 Male NOT HISPANIC OR LATINO ## 23 WHITE 1 Male HISPANIC OR LATINO ## 24 AMERICAN INDIAN OR ALASKA NATIVE 6 Male NOT HISPANIC OR LATINO ## 25 WHITE 1 Female HISPANIC OR LATINO ## 26 WHITE 1 Male NOT HISPANIC OR LATINO ## 27 WHITE 1 Male NOT HISPANIC OR LATINO ## 28 WHITE 1 Male NOT HISPANIC OR LATINO ## 29 WHITE 1 Male NOT HISPANIC OR LATINO ## 30 WHITE 1 Male NOT HISPANIC OR LATINO ## 31 WHITE 1 Female NOT HISPANIC OR LATINO ## 32 WHITE 1 Male NOT HISPANIC OR LATINO ## 33 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 34 WHITE 1 Female NOT HISPANIC OR LATINO ## 35 WHITE 1 Female NOT HISPANIC OR LATINO ## 36 WHITE 1 Male NOT HISPANIC OR LATINO ## 37 WHITE 1 Male NOT HISPANIC OR LATINO ## 38 WHITE 1 Female NOT HISPANIC OR LATINO ## 39 WHITE 1 Male NOT HISPANIC OR LATINO ## 40 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 41 WHITE 1 Male HISPANIC OR LATINO ## 42 WHITE 1 Female NOT HISPANIC OR LATINO ## 43 WHITE 1 Male NOT HISPANIC OR LATINO ## 44 WHITE 1 Male NOT HISPANIC OR LATINO ## 45 WHITE 1 Male NOT HISPANIC OR LATINO ## 46 WHITE 1 Female NOT HISPANIC OR LATINO ## 47 WHITE 1 Female NOT HISPANIC OR LATINO ## 48 WHITE 1 Female NOT HISPANIC OR LATINO ## 49 WHITE 1 Male NOT HISPANIC OR LATINO ## 50 WHITE 1 Male NOT HISPANIC OR LATINO ## 51 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 52 WHITE 1 Female NOT HISPANIC OR LATINO ## 53 WHITE 1 Female NOT HISPANIC OR LATINO ## 54 WHITE 1 Female NOT HISPANIC OR LATINO ## 55 WHITE 1 Female NOT HISPANIC OR LATINO ## 56 WHITE 1 Female NOT HISPANIC OR LATINO ## 57 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 58 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 59 WHITE 1 Male NOT HISPANIC OR LATINO ## 60 WHITE 1 Female NOT HISPANIC OR LATINO ## 61 WHITE 1 Female NOT HISPANIC OR LATINO ## 62 WHITE 1 Male NOT HISPANIC OR LATINO ## 63 WHITE 1 Male NOT HISPANIC OR LATINO ## 64 WHITE 1 Male NOT HISPANIC OR LATINO ## 65 WHITE 1 Female NOT HISPANIC OR LATINO ## 66 WHITE 1 Male NOT HISPANIC OR LATINO ## 67 WHITE 1 Female NOT HISPANIC OR LATINO ## 68 WHITE 1 Male NOT HISPANIC OR LATINO ## 69 WHITE 1 Male NOT HISPANIC OR LATINO ## 70 WHITE 1 Female NOT HISPANIC OR LATINO ## 71 WHITE 1 Female NOT HISPANIC OR LATINO ## 72 WHITE 1 Female NOT HISPANIC OR LATINO ## 73 WHITE 1 Female NOT HISPANIC OR LATINO ## 74 WHITE 1 Female NOT HISPANIC OR LATINO ## 75 WHITE 1 Female NOT HISPANIC OR LATINO ## 76 WHITE 1 Male NOT HISPANIC OR LATINO ## 77 WHITE 1 Female NOT HISPANIC OR LATINO ## 78 WHITE 1 Male NOT HISPANIC OR LATINO ## 79 WHITE 1 Female NOT HISPANIC OR LATINO ## 80 WHITE 1 Male NOT HISPANIC OR LATINO ## 81 WHITE 1 Male NOT HISPANIC OR LATINO ## 82 WHITE 1 Male NOT HISPANIC OR LATINO ## 83 WHITE 1 Male NOT HISPANIC OR LATINO ## 84 WHITE 1 Male NOT HISPANIC OR LATINO ## 85 WHITE 1 Male NOT HISPANIC OR LATINO ## 86 WHITE 1 Female NOT HISPANIC OR LATINO ## 87 WHITE 1 Female HISPANIC OR LATINO ## 88 WHITE 1 Female NOT HISPANIC OR LATINO ## 89 WHITE 1 Female NOT HISPANIC OR LATINO ## 90 WHITE 1 Male NOT HISPANIC OR LATINO ## 91 WHITE 1 Female NOT HISPANIC OR LATINO ## 92 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 93 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 94 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 95 WHITE 1 Male NOT HISPANIC OR LATINO ## 96 WHITE 1 Female NOT HISPANIC OR LATINO ## 97 WHITE 1 Female HISPANIC OR LATINO ## 98 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 99 WHITE 1 Male NOT HISPANIC OR LATINO ## 100 WHITE 1 Female NOT HISPANIC OR LATINO ## 101 WHITE 1 Female HISPANIC OR LATINO ## 102 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 103 WHITE 1 Female NOT HISPANIC OR LATINO ## 104 WHITE 1 Female NOT HISPANIC OR LATINO ## 105 WHITE 1 Female NOT HISPANIC OR LATINO ## 106 WHITE 1 Male NOT HISPANIC OR LATINO ## 107 WHITE 1 Male NOT HISPANIC OR LATINO ## 108 WHITE 1 Male NOT HISPANIC OR LATINO ## 109 WHITE 1 Female NOT HISPANIC OR LATINO ## 110 WHITE 1 Female NOT HISPANIC OR LATINO ## 111 WHITE 1 Female NOT HISPANIC OR LATINO ## 112 WHITE 1 Female NOT HISPANIC OR LATINO ## 113 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 114 WHITE 1 Female NOT HISPANIC OR LATINO ## 115 WHITE 1 Male NOT HISPANIC OR LATINO ## 116 WHITE 1 Female NOT HISPANIC OR LATINO ## 117 WHITE 1 Male NOT HISPANIC OR LATINO ## 118 WHITE 1 Male NOT HISPANIC OR LATINO ## 119 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 120 BLACK OR AFRICAN AMERICAN 2 Male NOT HISPANIC OR LATINO ## 121 WHITE 1 Male NOT HISPANIC OR LATINO ## 122 WHITE 1 Female NOT HISPANIC OR LATINO ## 123 WHITE 1 Male NOT HISPANIC OR LATINO ## 124 WHITE 1 Female NOT HISPANIC OR LATINO ## 125 WHITE 1 Female NOT HISPANIC OR LATINO ## 126 WHITE 1 Female NOT HISPANIC OR LATINO ## 127 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 128 WHITE 1 Male NOT HISPANIC OR LATINO ## 129 BLACK OR AFRICAN AMERICAN 2 Male NOT HISPANIC OR LATINO ## 130 WHITE 1 Female NOT HISPANIC OR LATINO ## 131 WHITE 1 Female NOT HISPANIC OR LATINO ## 132 WHITE 1 Female NOT HISPANIC OR LATINO ## 133 WHITE 1 Female NOT HISPANIC OR LATINO ## 134 WHITE 1 Female NOT HISPANIC OR LATINO ## 135 WHITE 1 Male NOT HISPANIC OR LATINO ## 136 WHITE 1 Female NOT HISPANIC OR LATINO ## 137 WHITE 1 Male NOT HISPANIC OR LATINO ## 138 WHITE 1 Female NOT HISPANIC OR LATINO ## 139 WHITE 1 Female NOT HISPANIC OR LATINO ## 140 WHITE 1 Female NOT HISPANIC OR LATINO ## 141 WHITE 1 Male NOT HISPANIC OR LATINO ## 142 WHITE 1 Male NOT HISPANIC OR LATINO ## 143 WHITE 1 Male NOT HISPANIC OR LATINO ## 144 WHITE 1 Male NOT HISPANIC OR LATINO ## 145 WHITE 1 Female NOT HISPANIC OR LATINO ## 146 WHITE 1 Female NOT HISPANIC OR LATINO ## 147 WHITE 1 Male NOT HISPANIC OR LATINO ## 148 WHITE 1 Female NOT HISPANIC OR LATINO ## 149 WHITE 1 Female NOT HISPANIC OR LATINO ## 150 WHITE 1 Male NOT HISPANIC OR LATINO ## 151 WHITE 1 Male NOT HISPANIC OR LATINO ## 152 WHITE 1 Male NOT HISPANIC OR LATINO ## 153 WHITE 1 Male NOT HISPANIC OR LATINO ## 154 WHITE 1 Male NOT HISPANIC OR LATINO ## 155 BLACK OR AFRICAN AMERICAN 2 Male NOT HISPANIC OR LATINO ## 156 WHITE 1 Male NOT HISPANIC OR LATINO ## 157 WHITE 1 Female NOT HISPANIC OR LATINO ## 158 WHITE 1 Female NOT HISPANIC OR LATINO ## 159 WHITE 1 Male NOT HISPANIC OR LATINO ## 160 WHITE 1 Female NOT HISPANIC OR LATINO ## 161 WHITE 1 Female NOT HISPANIC OR LATINO ## 162 WHITE 1 Female NOT HISPANIC OR LATINO ## 163 WHITE 1 Female NOT HISPANIC OR LATINO ## 164 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 165 WHITE 1 Female NOT HISPANIC OR LATINO ## 166 WHITE 1 Male HISPANIC OR LATINO ## 167 WHITE 1 Female NOT HISPANIC OR LATINO ## 168 WHITE 1 Female NOT HISPANIC OR LATINO ## 169 WHITE 1 Female NOT HISPANIC OR LATINO ## 170 WHITE 1 Female HISPANIC OR LATINO ## 171 WHITE 1 Male NOT HISPANIC OR LATINO ## 172 WHITE 1 Male NOT HISPANIC OR LATINO ## 173 WHITE 1 Female NOT HISPANIC OR LATINO ## 174 WHITE 1 Female NOT HISPANIC OR LATINO ## 175 WHITE 1 Male NOT HISPANIC OR LATINO ## 176 WHITE 1 Female NOT HISPANIC OR LATINO ## 177 WHITE 1 Female NOT HISPANIC OR LATINO ## 178 WHITE 1 Female NOT HISPANIC OR LATINO ## 179 WHITE 1 Male NOT HISPANIC OR LATINO ## 180 WHITE 1 Male NOT HISPANIC OR LATINO ## 181 WHITE 1 Female NOT HISPANIC OR LATINO ## 182 WHITE 1 Male NOT HISPANIC OR LATINO ## 183 WHITE 1 Male NOT HISPANIC OR LATINO ## 184 WHITE 1 Female NOT HISPANIC OR LATINO ## 185 BLACK OR AFRICAN AMERICAN 2 Male NOT HISPANIC OR LATINO ## 186 WHITE 1 Female NOT HISPANIC OR LATINO ## 187 WHITE 1 Female NOT HISPANIC OR LATINO ## 188 WHITE 1 Female NOT HISPANIC OR LATINO ## 189 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO ## 190 WHITE 1 Male NOT HISPANIC OR LATINO ## 191 WHITE 1 Male NOT HISPANIC OR LATINO ## 192 WHITE 1 Female NOT HISPANIC OR LATINO ## 193 WHITE 1 Female NOT HISPANIC OR LATINO ## 194 WHITE 1 Male NOT HISPANIC OR LATINO ## 195 WHITE 1 Male NOT HISPANIC OR LATINO ## 196 WHITE 1 Female NOT HISPANIC OR LATINO ## 197 WHITE 1 Female NOT HISPANIC OR LATINO ## 198 WHITE 1 Female NOT HISPANIC OR LATINO ## 199 WHITE 1 Male NOT HISPANIC OR LATINO ## 200 BLACK OR AFRICAN AMERICAN 2 Male NOT HISPANIC OR LATINO ## 201 WHITE 1 Female NOT HISPANIC OR LATINO ## 202 WHITE 1 Male NOT HISPANIC OR LATINO ## 203 WHITE 1 Female NOT HISPANIC OR LATINO ## 204 WHITE 1 Male NOT HISPANIC OR LATINO ## 205 WHITE 1 Female NOT HISPANIC OR LATINO ## 206 WHITE 1 Female NOT HISPANIC OR LATINO ## 207 WHITE 1 Male NOT HISPANIC OR LATINO ## 208 WHITE 1 Female NOT HISPANIC OR LATINO ## 209 WHITE 1 Female NOT HISPANIC OR LATINO ## 210 WHITE 1 Male NOT HISPANIC OR LATINO ## 211 WHITE 1 Female NOT HISPANIC OR LATINO ## 212 WHITE 1 Female NOT HISPANIC OR LATINO ## 213 WHITE 1 Female NOT HISPANIC OR LATINO ## 214 WHITE 1 Male NOT HISPANIC OR LATINO ## 215 WHITE 1 Male NOT HISPANIC OR LATINO ## 216 WHITE 1 Female NOT HISPANIC OR LATINO ## 217 WHITE 1 Male NOT HISPANIC OR LATINO ## 218 WHITE 1 Male NOT HISPANIC OR LATINO ## 219 WHITE 1 Female NOT HISPANIC OR LATINO ## 220 WHITE 1 Female NOT HISPANIC OR LATINO ## 221 WHITE 1 Male NOT HISPANIC OR LATINO ## 222 WHITE 1 Female NOT HISPANIC OR LATINO ## 223 WHITE 1 Male NOT HISPANIC OR LATINO ## 224 WHITE 1 Male NOT HISPANIC OR LATINO ## 225 WHITE 1 Male NOT HISPANIC OR LATINO ## 226 WHITE 1 Female NOT HISPANIC OR LATINO ## 227 WHITE 1 Female NOT HISPANIC OR LATINO ## 228 WHITE 1 Female NOT HISPANIC OR LATINO ## 229 WHITE 1 Male NOT HISPANIC OR LATINO ## 230 WHITE 1 Female NOT HISPANIC OR LATINO ## 231 WHITE 1 Male NOT HISPANIC OR LATINO ## 232 WHITE 1 Female NOT HISPANIC OR LATINO ## 233 WHITE 1 Male NOT HISPANIC OR LATINO ## 234 WHITE 1 Female NOT HISPANIC OR LATINO ## 235 WHITE 1 Female NOT HISPANIC OR LATINO ## 236 WHITE 1 Male NOT HISPANIC OR LATINO ## 237 WHITE 1 Male NOT HISPANIC OR LATINO ## 238 WHITE 1 Female NOT HISPANIC OR LATINO ## 239 WHITE 1 Female NOT HISPANIC OR LATINO ## 240 WHITE 1 Male NOT HISPANIC OR LATINO ## 241 WHITE 1 Female NOT HISPANIC OR LATINO ## 242 WHITE 1 Female NOT HISPANIC OR LATINO ## 243 WHITE 1 Female NOT HISPANIC OR LATINO ## 244 BLACK OR AFRICAN AMERICAN 2 Male NOT HISPANIC OR LATINO ## 245 WHITE 1 Male NOT HISPANIC OR LATINO ## 246 WHITE 1 Female NOT HISPANIC OR LATINO ## 247 WHITE 1 Female NOT HISPANIC OR LATINO ## 248 WHITE 1 Male NOT HISPANIC OR LATINO ## 249 WHITE 1 Female HISPANIC OR LATINO ## 250 WHITE 1 Male HISPANIC OR LATINO ## 251 WHITE 1 Male NOT HISPANIC OR LATINO ## 252 WHITE 1 Male NOT HISPANIC OR LATINO ## 253 WHITE 1 Female NOT HISPANIC OR LATINO ## 254 BLACK OR AFRICAN AMERICAN 2 Female NOT HISPANIC OR LATINO "],["methods.html", "8 Methods", " 8 Methods We describe our methods in this chapter. "],["applications.html", "9 Applications 9.1 Example one 9.2 Example two", " 9 Applications Some significant applications are demonstrated in this chapter. 9.1 Example one 9.2 Example two "],["final-words.html", "10 Final Words", " 10 Final Words We have finished a nice book. "],["references.html", "References", " References "]]
